Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:8398828rdf:typepubmed:Citationlld:pubmed
pubmed-article:8398828lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:8398828lifeskim:mentionsumls-concept:C0332307lld:lifeskim
pubmed-article:8398828lifeskim:mentionsumls-concept:C0023473lld:lifeskim
pubmed-article:8398828lifeskim:mentionsumls-concept:C0004891lld:lifeskim
pubmed-article:8398828lifeskim:mentionsumls-concept:C0038952lld:lifeskim
pubmed-article:8398828lifeskim:mentionsumls-concept:C0681842lld:lifeskim
pubmed-article:8398828lifeskim:mentionsumls-concept:C0205144lld:lifeskim
pubmed-article:8398828pubmed:issue2lld:pubmed
pubmed-article:8398828pubmed:dateCreated1993-11-4lld:pubmed
pubmed-article:8398828pubmed:abstractTextThe prognostic value of the location of the breakpoint on chromosome 22 in patients with Ph1+ chronic myeloid leukaemia (CML) is still controversial. We analysed both DNA rearrangement and transcript type in a new continuous series of CML patients. By Southern blotting analysis, we found that, out of 72 patients, 43 had a 5' rearrangement and 29 a 3' one, of the 43 5'-rearranged patients, 35 carried an a2b2 transcript and eight an a2b3 one, while, of the 29 patients rearranged in the 3' part of the M-BCR area, 26 had an a2b3 transcript, one had an a2b2 transcript and two carried both types of transcript. Thus, mRNA studies allow to detect an a2b3 transcript in 17.7% of 5' rearranged patients. However, no correlation was observed between type of transcript and survival, as after DNA studies.lld:pubmed
pubmed-article:8398828pubmed:languageenglld:pubmed
pubmed-article:8398828pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8398828pubmed:citationSubsetIMlld:pubmed
pubmed-article:8398828pubmed:statusMEDLINElld:pubmed
pubmed-article:8398828pubmed:monthJunlld:pubmed
pubmed-article:8398828pubmed:issn0007-1048lld:pubmed
pubmed-article:8398828pubmed:authorpubmed-author:AmbrosettiAAlld:pubmed
pubmed-article:8398828pubmed:authorpubmed-author:BaccaraniMMlld:pubmed
pubmed-article:8398828pubmed:authorpubmed-author:ZaccariaAAlld:pubmed
pubmed-article:8398828pubmed:authorpubmed-author:MartinelliGGlld:pubmed
pubmed-article:8398828pubmed:authorpubmed-author:RussoDDlld:pubmed
pubmed-article:8398828pubmed:authorpubmed-author:BuzziMMlld:pubmed
pubmed-article:8398828pubmed:authorpubmed-author:TestoniNNlld:pubmed
pubmed-article:8398828pubmed:authorpubmed-author:ZuffaEElld:pubmed
pubmed-article:8398828pubmed:authorpubmed-author:ZamagniM DMDlld:pubmed
pubmed-article:8398828pubmed:authorpubmed-author:FarabegoliPPlld:pubmed
pubmed-article:8398828pubmed:issnTypePrintlld:pubmed
pubmed-article:8398828pubmed:volume84lld:pubmed
pubmed-article:8398828pubmed:ownerNLMlld:pubmed
pubmed-article:8398828pubmed:authorsCompleteNlld:pubmed
pubmed-article:8398828pubmed:pagination265-8lld:pubmed
pubmed-article:8398828pubmed:dateRevised2007-11-15lld:pubmed
pubmed-article:8398828pubmed:meshHeadingpubmed-meshheading:8398828-...lld:pubmed
pubmed-article:8398828pubmed:meshHeadingpubmed-meshheading:8398828-...lld:pubmed
pubmed-article:8398828pubmed:meshHeadingpubmed-meshheading:8398828-...lld:pubmed
pubmed-article:8398828pubmed:meshHeadingpubmed-meshheading:8398828-...lld:pubmed
pubmed-article:8398828pubmed:meshHeadingpubmed-meshheading:8398828-...lld:pubmed
pubmed-article:8398828pubmed:meshHeadingpubmed-meshheading:8398828-...lld:pubmed
pubmed-article:8398828pubmed:meshHeadingpubmed-meshheading:8398828-...lld:pubmed
pubmed-article:8398828pubmed:meshHeadingpubmed-meshheading:8398828-...lld:pubmed
pubmed-article:8398828pubmed:meshHeadingpubmed-meshheading:8398828-...lld:pubmed
pubmed-article:8398828pubmed:meshHeadingpubmed-meshheading:8398828-...lld:pubmed
pubmed-article:8398828pubmed:meshHeadingpubmed-meshheading:8398828-...lld:pubmed
pubmed-article:8398828pubmed:meshHeadingpubmed-meshheading:8398828-...lld:pubmed
pubmed-article:8398828pubmed:meshHeadingpubmed-meshheading:8398828-...lld:pubmed
pubmed-article:8398828pubmed:meshHeadingpubmed-meshheading:8398828-...lld:pubmed
pubmed-article:8398828pubmed:meshHeadingpubmed-meshheading:8398828-...lld:pubmed
pubmed-article:8398828pubmed:meshHeadingpubmed-meshheading:8398828-...lld:pubmed
pubmed-article:8398828pubmed:year1993lld:pubmed
pubmed-article:8398828pubmed:articleTitleThe type of BCR/ABL junction does not predict the survival of patients with Ph1-positive chronic myeloid leukaemia.lld:pubmed
pubmed-article:8398828pubmed:affiliationIstituto di Ematologia Lorenzo e Ariosto Seràgnoli, Università di Bologna, Italia.lld:pubmed
pubmed-article:8398828pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:8398828pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed